<DOC>
	<DOCNO>NCT01261143</DOCNO>
	<brief_summary>The purpose study determine : Primary end point - change Total symptom score Secondary end point - neurological test</brief_summary>
	<brief_title>Randomized , Double-blind Study Assess Efficacy Safety α-lipoic Acid Versus BK-C-0701 Subjects With Diabetic Neuropathy</brief_title>
	<detailed_description>total symptom score shall calculate data burning , numbness , stab pain , paraesthesiae .</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Diabetes mellitus ( Type I II ) , define American Diabetes Association , 1997 , last 1 year wellcontrolled . Patient symmetric sensorymotor Diabetic Neuropathy stage 2 Result pinprick test 'absent ' 'reduced ' HbA1C &lt; 10 % Total Symptom Score ≥ 4 point At least 1 4 symptom TSS must occur continuously last 3 month . Patient 19 year age Female postmenopausal willing use effective method contraception study ( Effective method=IUD , spermicide condom , abstinence ) surgically sterile ( underwent total hysterectomy bilateral tubal ligation ) . Patient Proximal asymmetric neuropathy , cranial neuropathy , truncal radiculopathy , diabetic plexopathies , acute active mononeuropathy ( cranial neuropathy , postherpes neuralgias ) Patient Neuropathy alcohol , drug ( cisplatin , taxol , etcs ) , malignant cancer medical history nerve system disease Parkinson 's disease/ epilepsy/ Multiple sclerosis , etcs . Patient nerve system disease cause sensory loss Myopathy cause . Peripheral vascular disease severe enough cause ischemic ulcer limb ischemia . Patients diabetic proliferate retinopathy require immediately therapy impend blindness . Patients active neoplastic disease except benign tumor nonrecurrent malignant tumor 5 year . Patients clinically significant cardiac , pulmonary , gastrointestinal , haematological , endocrine disease may confound interpretation study result prevent patient completing study . Patients atrial fibrillation . Patients organ transplant kind . Patients significant hepatic renal disease ( AST , ALT GGT &gt; 2 time normal , serum creatinine &gt; 1.8 mg/dL ( &gt; 159 mmol/l ) males &gt; 1.6 mg/dL ( &gt; 141 mmol/l ) female ) . Patients recent history ( within last 12 month ) drug alcohol abuse . Use investigational drug ( participation clinical trial ) within last 1 month . History severe anaphylactic reaction drug , sulfur biologic product . Recent ( within last 3 month ) ketoacidosis hypoglycaemia , necessitate hospital admission . Existing foot ulcer . Pregnant lactating female History allergic reaction study medication excipients . Psychiatric , psychological , behavioural symptom would interfere patient 's ability participate trial . Patient suitable trial investigator judgment . Patient write inform consent prior start trial comply trial requirement . Antioxidant therapy ( vitamin E &gt; 400 IU , C &gt; 200 mg , betaCarotene &gt; 30 mg ) pentoxyphylline within last 1 month start trial . Use thioctic acid ( &gt; 50 mg ) , even primrose oil gammalinolenic acid contain substance within last 3 month . Use analgesic within &gt; 5times halflife administration investigational medication . Use anticonvulsant ( include Pregabalin ) , antidepressant within 4 week administration investigational medication .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>